News | December 17, 2024
SPARC signs LoI with UCSF and Tiller Therapeutics for pre-clinical oncology asset and associated IP
SPARC to receive 55% equity in Tiller Therapeutics
SPARC to receive 55% equity in Tiller Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
At 24 months, data from the Phase 1 exPDite trial continue to show a favorable safety profile in all 12 participants in the trial’s high and low dose cohorts
This partnership aims to accelerate research and development into innovative treatments and, if successful, will generate milestones and royalties
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
